Published: 5 March 2020
Publications
Recent approvals of medicines containing a new active ingredient
Prescriber Update 41(1): 12
March 2020
For period 16 October 2019 to 15 January 2020.
| Trade Name (Active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Besponsa (inotuzumab osogamicin) | Powder for injection 1 mg | Acute lymphoblastic leukaemia |
| Erlyand (apalutamide) | Film coated tablet 60 mg | Prostate cancer |
| Odomzo (sonidegib) | Capsule 200 mg | Basal cell carcinoma |
| Rydapt (midostaurin) | Soft gelatin capsule 25 mg | Acute myeloid leukaemia, aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasms, mast cell leukaemia |
| Spravato (esketamine) | Nasal spray solution 140 mg/mL | Depression |
See
the Medsafe website for more information about these medicines.
Data sheets
of currently marketed medicines are also available.
